Handbook of Hematologic Malignancies 2/e

Name: Handbook of Hematologic Malignancies 2/e
Brand: SPRINGER PUBLISHING COMPANY
SKU: 9780826149763
Price: 160.0 AUD
Availability: InStock

SPRINGER PUBLISHING COMPANYISBN: 9780826149763

Price:

$160.00

Stock:

In stock

Quantity:

By David A. Sallman, Ateefa Chaudhury, Johnny Nguyen, Ling Zhang, Alan F. List
Imprint: SPRINGER PUBLISHING COMPANY
Release Date: October 21, 2021
Format: PAPERBACK
Pages: 500

Share this product

This revised and updated second edition of Handbook of Hematologic Malignancies continues to be an essential and "go-to" resource for the busy hematologist, hematologic oncologist, hematopathologist, oncology advanced practice provider, oncology nurse, and trainee. Concisely organized, each chapter provides the most current, need-to-know points of diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematological malignancy. Chapters are complete with richly illustrated figures to highlight the hematopathologic characteristics of diseases in addition to helpful tables on differential diagnosis, prognostic scoring systems, molecular profiles, and therapeutic options. A new case-based chapter concludes the handbook with clinical cases designed to test a clinician's knowledge of pathologic diagnosis and clinical presentation of diseases covered in the book. With over twenty new FDA-approved indications since publication of the first edition, including breakthroughs with CAR-T therapy, and other evidence-based treatment options for patients with hematologic disease, this book serves as quick reference to practice changing information on challenging diagnostic dilemmas, frontline and refractory treatment scenarios, and more.The subspecialty field of hematologic oncology is ever-changing and expanding with available treatment options and this second edition keeps the busy clinician abreast of recent findings and their impact on evidence-based treatment and management. Written by experienced clinicians at the world-renowned Moffitt Cancer Center in Tampa, Florida, as well as contributions from leading academicians, hematologists, and oncologists throughout the country, this unique handbook is packed with authoritative knowledge and clinical insight into all known hematologic cancers. Key Features: Includes seven new chapters covering CAR-T and novel therapeutic options including CD19 CAR-T therapy, novel cellular therapies, cytokine release syndrome, cancer associated thrombosis, and more Comprises compact and updated disease-site chapters describing new standards of care and management considerations in bullet point format with key references Highlights important diagnostic tools that assist with conducting key differential diagnoses and unveiling answers to diagnostic dilemmas Provides updates of potential practice-changing clinical trials and paradigm shifting treatment considerations in each disease-based chapter Purchase includes digital access for use on most mobile devices or computers

Contributors Preface PART I: INTRODUCTION AND OVERVIEW Chapter 1. Normal Hematopoiesis and Diagnosis Algorithms for Cytopenias and Cytoses Chapter 2. Familial/Inherited Mutations and Risks of Hematologic Malignancies Chapter 3. Hematopathology Diagnostic Techniques and Assays Chapter 4. Minimal Residual Disease Assays PART II: MYELOPROLIFERATIVE NEOPLASMS Chapter 5. Polycythemia Vera Chapter 6. Essential Thrombocythemia Chapter 7. Primary Myelofibrosis Chapter 8. Chronic Myelogenous Leukemia Chapter 9. Chronic Neutrophilic Leukemia Chapter 10. Systemic Mastocytosis Chapter 11. PDGFRA/PDGFRB/FGFR1 Myeloid Neoplasms PART III: MYELODYSPLASTIC AND BONE MARROW FAILURE SYNDROMES Chapter 12. Myelodysplastic Syndromes Chapter 13. Aplastic Anemia Chapter 14. Paroxysmal Nocturnal Hemoglobinuria PART IV: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS Chapter 15. Myelodysplastic/Myeloproliferative Overlap Syndromes Chapter 16. Chronic Myelomonocytic Leukemia PART V: ACUTE MYELOID LEUKEMIA AND RELATED SYNDROMES Chapter 17. Acute Myeloid Leukemia Chapter 18. Secondary AML and AML With Myelodysplasia-Related Changes Chapter 19. Acute Promyelocytic Leukemia Chapter 20. Blastic Plasmacytoid Dendritic Cell Neoplasm PART VI: ACUTE LYMPHOID LEUKEMIA Chapter 21. B-Lymphoblastic Leukemia/Lymphoma Chapter 22. BCR-ABL1 B-Lymphoblastic Leukemia Chapter 23. T-Lymphoblastic Lymphoma/Leukemia PART VII: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE Chapter 24. Acute Leukemia of Ambiguous Lineage PART VIII: MATURE T- AND NK-CELL LEUKEMIA Chapter 25. T-Cell Prolymphocytic Leukemia Chapter 26. T-Cell Large Granular Lymphocytic Leukemia Chapter 27. Aggressive Natural Killer Cell Leukemia PART IX: PLASMA CELL DISORDERS Chapter 28. Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and Plasmacytomas Chapter 29. Multiple Myeloma Chapter 30. Waldenstroem's Macroglobulinemia Chapter 31. Immunoglobulin Light Chain Amyloidosis PART X: HODGKIN LYMPHOMA Chapter 32. Hodgkin Lymphoma PART XI: NON-HODGKIN LYMPHOMA Chapter 33. Non-Hodgkin Lymphoma Classification and Diagnostic Evaluation PART XII: MATURE B-CELL LYMPHOMA VERY AGGRESSIVE Chapter 34. Burkitt Lymphoma AGGRESSIVE Chapter 35. Diffuse Large B-Cell Lymphoma Chapter 36. Double Hit Lymphoma Chapter 37. Mantle Cell Lymphoma Chapter 38. Primary Mediastinal Large B-Cell Lymphoma Chapter 39. Primary Central Nervous System Lymphoma Chapter 40. HIV-Related Lymphomas INDOLENT Chapter 41. Follicular Lymphoma Chapter 42. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chapter 43. Hairy Cell Leukemia Chapter 44. Marginal Zone Lymphoma Chapter 45. Mucosa-Associated Lymphoid Tissue Lymphoma PART XIII: MATURE T/NK-CELL LYMPHOMA Chapter 46. Adult T-Cell Leukemia/Lymphoma Chapter 47. Anaplastic Large Cell Lymphoma, ALK Positive Chapter 48. Extranodal Natural Killer/T-Cell Lymphoma Chapter 49. Mycosis Fungoides Chapter 50. Hepatosplenic T-Cell Lymphoma PART XIV: HISTIOCYTIC/DENDRITIC CELL NEOPLASMS Chapter 51. Histiocytic Sarcoma, Langerhans Cell Histiocytosis, Erdheim-Chester Disease, and Rosai-Dorfman Disease Chapter 52. Hemophagocytic Lymphohistiocytosis PART XV: BONE MARROW TRANSPLANTATION Chapter 53. Autologous Bone Marrow Transplantation Chapter 54. Allogeneic Bone Marrow Transplantation PART XVI: NEW CELLULAR IMMUNOTHERAPY Chapter 55. CAR-T and Novel Cellular Therapeutic Options in Hematologic Malignancies Chapter 56. CD19 CAR-T Therapy Chapter 57. Cytokine Release Syndrome PART XVII: EMERGENCIES IN HEMATOLOGY Chapter 58. Cancer Associated Thrombosis Chapter 59. Tumor Lysis Syndrome Chapter 60. Thrombotic Microangiopathy Chapter 61. Therapeutic Apheresis Indications PART XVIII: NEW CLINICAL CASES IN MALIGNANT HEMATOLOGY Chapter 62. Challenging Case Vignettes with Follow-Up Questions Appendix: Pathology Supplement

David A Sallman, MD is Malignant Oncology Fellow, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, c/o Moffitt Cancer Center and Research Institute, Tampa, FL "Malignant Oncology Fellow, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, c/o Moffitt Cancer Center and Research Institute, Tampa, FL" "Pathology Resident, Department of Pathology, Morsani College of Medicine, University of South Florida, Tampa, FL" "Associate Professor, Department of Pathology, Morsani College of Medicine, University of South Florida, c/o Moffitt Cancer Center and Research Institute, Tampa, FL" "CEO, Moffitt Cancer Center and Research Institute; and Professor, Department of Internal Medicine and Oncology, University of South Florida College of Medicine, Tampa, FL".

Recover password

Handbook of Hematologic Malignancies 2/e

Description

You may also like

Recently viewed